Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MNKD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMannKind released from FDA postmarketing trial requirement for Afrezza diabetes drug
Filed May 28, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
high
FDA released MannKind from a major postmarketing requirement mandating a 5-year trial in 8,000-10,000 patients to assess lung cancer risk, eliminating a significant regulatory burden that had been in place since 2014 approval.
Item 8.01 verify on EDGAR → -
high
FDA decision on pediatric supplemental application for Afrezza in children aged 4-17 with diabetes is due May 29, 2026 (one day after this filing), which could expand the addressable market if approved.
Item 8.01 verify on EDGAR → -
medium
Company expanded INHALE-1st trial to 10 sites enrolling up to 100 youth patients aged 10-17 with newly-diagnosed type 1 diabetes, with data expected in late 2027 to support additional pediatric indications.
Item 8.01 verify on EDGAR →
Summary
MannKind received significant regulatory relief when the FDA released the company from a postmarketing requirement that had hung over Afrezza since its 2014 approval.
The requirement would have forced MannKind to conduct a massive 5-year trial in thousands of patients to monitor for lung cancer risk—a costly and time-consuming obligation that created ongoing uncertainty about the inhaled insulin product's safety profile. The release suggests the FDA is satisfied with existing safety data.
The timing is notable because MannKind is simultaneously awaiting an FDA decision on expanding Afrezza to pediatric patients aged 4-17, with the regulatory deadline hitting tomorrow (May 29, 2026). Approval would open a new market segment for the product. The company is also advancing a separate clinical trial in newly-diagnosed youth with type 1 diabetes, with results expected in late 2027. Retail investors should watch for the pediatric approval decision in the next 24-48 hours, as it represents the most immediate catalyst. The postmarketing requirement release removes a long-term overhang but doesn't change near-term fundamentals unless it affects physician prescribing behavior or payer coverage decisions.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
In October 2025, the FDA accepted for review a supplemental BLA for Afrezza in children and adolescents between the ages of 4-17 who are living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026.
MannKind has a pending supplemental BLA for Afrezza in pediatric patients aged 4-17 with type 1 or type 2 diabetes. The FDA's PDUFA target action date is May 29, 2026, meaning a regulatory decision is imminent (one day after this filing). Approval would expand Afrezza's addressable market to include pediatric patients.
Added in current filing · verify on EDGAR →
An additional eight sites have been activated to enroll participants into INHALE-1st, a study to evaluate the efficacy and safety of Afrezza plus basal insulin for youth aged 10-17 with newly-diagnosed type 1 diabetes. Up to 100 participants are expected to be enrolled in this study across 10 clinical sites.
MannKind expanded its INHALE-1st clinical trial by activating eight additional sites, bringing the total to 10 sites enrolling up to 100 youth participants aged 10-17 with newly-diagnosed type 1 diabetes. The trial evaluates Afrezza plus basal insulin over 13 weeks with an optional 26-week extension. Data is expected in late 2027, which could support further pediatric indications.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify